Drug Trial Radar · NCT03474029
Assessment of the Safety, Tolerability, and Effectiveness of Rifapentine Given Daily for LTBI
Last checked: Nov 19, 2026Latest source record: May 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
3,400
Planned (sponsor's estimate)
Start
Aug 1, 2019
Primary completion
Dec 31, 2029
Study completion Dec 31, 2029
Sponsor
- Lead sponsor
- Centers for Disease Control and PreventionFederal agency
- Sponsor type
- Federal agency
- First posted
- Mar 22, 2018
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is conducted to compare the safety and effectiveness of a novel short 6-week regimen of daily rifapentine (6wP, experimental arm) with a comparator arm of 12-16 weeks of rifamycin-based treatment (standard of care, control arm) of latent M. tuberculosis infection (LTBI). This trial is conducted among persons who are at increased risk of progression to tuberculosis (TB) and require treatment of LTBI. The study will be conducted in low, medium and high TB incidence settings that have treatment of LTBI as their standard of care and offer 12-16 week rifamycin-based therapy as standard of care. The hypothesis of this study is that the safety and effectiveness of the experimental treatment (6wP arm) is non-inferior to a comparator arm of 12-16 weeks of rifamycin-based treatment of LTBI (control arm). Participants are enrolled and randomly assigned to one of the two study arms: experimental 6wP or control. The comparator (control) arm's treatment regimens include 12 weeks of once-weekly isoniazid (INH) and rifapentine (3HP), 12 weeks of daily INH and rifampin (3HR), and 16 weeks of daily rifampin (4R). A total of 560 participants per arm (1,120 total) for the evaluation of safety and 1,700 participants per arm (3,400 total) for the evaluation of effectiveness will be enrolled, given treatment as per randomization assignment, and followed for 24 months from the date of enrollment. After completion of data collection, statistical analyses will be conducted to compare proportions of drug discontinuation due to adverse drug reaction (ADR) and proportions of newly diagnosed tuberculosis between 6wP and control arm.
Conditions
- Latent Tuberculosis
Interventions
Rifapentine daily for 6 weeksDrug
600 mg of Rifapentine (RPT) given once daily (o.d., omni die) for 6 weeks (6wP).
Rifapentine and Isoniazid weekly for 12 weeksDrug
Rifapentine (RPT) 900 mg and isoniazid (INH) 900 mg given once-weekly for 12 weeks (3HP).\* \*Dose adjustments based on patient's weight will be made according to ATS/CDC/IDSA guidelines. RPT 900 mg once-weekly for persons weighing \> 50 kg. For persons weighing \< 50 kg, the following doses will be given: weight \> 25-32 kg - RPT 600 mg; weight \> 32-50 kg - RPT 750 mg; + INH 15 mg/kg (round up to nearest 50 or 100 mg; 900 mg max).
Rifampin and Isoniazid daily for 12 weeksDrug
Rifampin (RIF) 600 mg and Isoniazid (INH) 300 mg given once-daily for 12 weeks (3HR)\*. \*Dose adjustments based on patient's weight will be made according to ATS/CDC/IDSA guidelines. RIF 600 mg daily for persons weighing \> 50 kg. For persons weighing \< 50 kg, give 10 mg/kg daily; round up to nearest 50 or 100 mg; + INH 5 mg/kg daily (rounded up to nearest 50 or 100 mg; 300 mg max).
Rifampin daily for 16 weeksDrug
Rifampin (RIF) 600 mg given once-daily for 16 weeks (4R).\* \*Dose adjustments based on patient's weight will be made according to ATS/CDC/IDSA guidelines. RIF 600 mg daily for persons weighing \> 50 kg. For persons weighing \< 50 kg, 10 mg/kg daily; round up to nearest 50 or 100 mg.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Treatment discontinuation due to adverse drug reactionTime frame: from the date of enrollment to the date of scheduled completion of assigned treatment
- Culture-confirmed tuberculosis (TB) in participants 18 years old and older and culture-confirmed or clinical TB in participants less then 18 years old.Time frame: within 24 months from the date of enrollment
Locations
21 sites in 8 countries. Site status is shown where the registry gives one.
Denver Health and Hospital Authority
Denver, Colorado · Recruiting
George Washington University
Washington D.C., District of Columbia · Recruiting
Washington DC VA Medical Center
Washington D.C., District of Columbia · Recruiting
New York Harbor Healthcare System
Manhattan, New York · Recruiting
New York City Bureau of TB Control
New York, New York · Recruiting
San Antonio VA
San Antonio, Texas · Active not recruiting
Seattle King County Health Department
Seattle, Washington · Recruiting
Liverpool Hospital
Sydney, Australia · Recruiting
Paramatta Chest
Sydney, Australia · Recruiting
Royal Prince Alfred Hospital
Sydney, Australia · Recruiting
National Referral University Hospital for Pneumo-physiology
Cotonou, Benin · Active not recruiting
Calgary TB Clinic
Calgary, Alberta, Canada · Recruiting
Edmonton TB Clinic
Edmonton, Alberta, Canada · Recruiting
British Columbia Centre for Disease Control
Vancouver, British Columbia, Canada · Recruiting
Toronto Western Hospital
Toronto, Ontario, Canada · Recruiting
McGill University Health Centre
Montreal, Quebec, Canada · Recruiting
Les Centres Gheskio (INLR) CRS
Port-au-Prince, Haiti · Recruiting
Desmond Tutu TB Center
Stellenbosch, South Africa · Not yet recruiting
Joint Clinical Research Centre/ Makerere Univ Med Sch
Kampala, Uganda · Recruiting
Ho Chin Minh City-District 6 TB Unit
Ho Chi Minh City, Vietnam · Recruiting
Ho Chin Minh City-Phoi Viet Resportory Centre
Ho Chi Minh City, Vietnam · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.